Fusion Antibodies announce F.A.A.S.T. sequencing service

The Fusion Antibodies Accelerated Sequencing Technology service will offer an option to researches and SMEs

Today we have proudly announced a new, lower-cost, rapid turnaround Antibody Sequencing service. The new F.A.A.S.T (Fusion Antibodies Accelerated Sequencing Technology) service will offer an option to researches and SME’s who may not require the level of detail provided by our standard sequencing services. 

While we have previously offered three guaranteed sequencing services which range from variable domain only to full length antibody sequencing we seen a gap in the market to offer something new. Although our standard service options include aberrant light chain identification, CDR identification, a minimum 5-strong consensus and a detailed technical report, some clients did not require this level of detail. The new F.A.A.S.T service will fill this gap in the market and allow wider access to high quality antibody sequencing and result in more novel drugs entering the clinic faster.

Richard Buick, Chief Scientific Officer at Fusion Antibodies commented: “Fusion Antibodies have went from strength to strength recently and the announcement of this new service marks an important milestone in the evolution of Fusion Antibodies to meet the needs of our customers. We aim to add real value to our client’s projects and hope this new service allows Fusion Antibodies to grow and develop even further”.

The new service is available from today and Fusion Antibodies Business Development executive Andrew Glover added: “We are keen to get started with this new service and look forward to offering some extra incentives to the first few customers!” More details about the service are available on the antibody sequencing page ( or by contacting a member of the Fusion Antibodies team.